Searched for: in-biosketch:true
person:spenck04
Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy
Neibart, Shane S.; Mamidanna, Swati; Chundury, Anupama; Sayan, Mutlay; Alexander, H. Richard; August, David A.; Berim, Lyudmyla D.; Boland, Patrick M.; Grandhi, Miral S.; Gulhati, Prateek; Hochster, Howard S.; Langan, Russell C.; Spencer, Kristen R.; Kennedy, Timothy J.; Deek, Matthew P.; Jabbour, Salma K.
ISI:000719385100001
ISSN: 2078-6891
CID: 5754752
Predictors of Undergoing Surgical Resection after Neoadjuvant Chemoradiotherapy for Borderline Resectable and Resectable Pancreatic Adenocarcinoma [Meeting Abstract]
Neibart, S. S.; Mamidanna, S.; Chundury, A.; Sayan, M.; Alexander, H. R.; August, D.; Berim, L. D.; Boland, P. M.; Grandhi, M. S.; Gulhati, P.; Kennedy, T. J.; Langan, R. C.; Spencer, K.; Jabbour, S. K.
ISI:000715803800082
ISSN: 0360-3016
CID: 5754762
Comparing Acute Toxicities of Patients With Unresectable Hepatocellular Carcinoma Treated With Definitive Proton vs. Photon-Based Radiotherapy [Meeting Abstract]
Mamidanna, S.; Neibart, S. S.; Chundury, A.; Sayan, M.; Alexander, H. R.; August, D.; Berim, L. D.; Boland, P. M.; Grandhi, M. S.; Gulhati, P.; Gupta, K.; Hochster, H. S.; Kennedy, T. J.; Langan, R. C.; Minacapelli, C. C.; Spencer, K.; Nosher, J.; Jabbour, S. K.
ISI:000715803800068
ISSN: 0360-3016
CID: 5754772
PHASE 1 STUDY OF INCB086550, AN ORAL PD-L1 INHIBITOR, IN IMMUNE-CHECKPOINT NAIVE PATIENTS WITH ADVANCED SOLID TUMORS [Meeting Abstract]
Van Cutsem, Eric; Prenen, Hans; Delafontaine, Brant; Spencer, Kristen; Mitchell, Tara; Burris, Howard; Kotecki, Nuria; Kristeleit, Rebecca; Pinato, David; Sahebjam, Solmaz; Graham, Donna; Karasic, Thomas; Daniel, Jeannie; O\Hayer, Kevin; Geschwindt, Ryan; Piha-Paul, Sarina
ISI:000774877500508
ISSN: 2051-1426
CID: 5381472
A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in-A trial of the ECOG-ACRIN Cancer Research Group (EA2174). [Meeting Abstract]
Eads, Jennifer Rachel; Weitz, Michelle; Catalano, Paul J.; Gibson, Michael K.; Rajdev, Lakshmi; Khullar, Onkar; Lin, Steven H.; Gatsonis, Constantine; Wistuba, Ignacio Ivan; Sanjeevaiah, Aravind; Benson, Al Bowen; Bahary, Nathan; Spencer, Kristen Renee; Saba, Nabil F.; Hamilton, Stanley R.; Staley, Charles A.; Chakravarthy, Bapsi; Fisher, George A.; Wong, Terence Z.; O\Dwyer, Peter J.
ISI:000708120602164
ISSN: 0732-183x
CID: 5180762
Mamidanna, S., Neibart, S.S., Chundury, A., Sayan, M., Alexander, H.R., August, D., Berim, L.D., Boland, P.M., Grandhi, M.S., Gulhati, P., Gupta, K., Hochster, H.S., Kennedy, T.J., Langan, R.C., Minacapelli, C.C., Spencer, K., Nosher, J., Jabbour, S.K.
Purpose/Objective(s)Radiation therapy (RT) is a critical modality for the treatment of unresectable hepatocellular carcinoma (HCC). Little is known about how the etiology of HCC impacts overall and progression free survival (OS and PFS) in patients treated with definitive RT. We hypothesize that patients treated with definitive RT for HCC secondary to hepatitis B and hepatitis C viruses (viral group) would have favorable OS and PFS when compared to patients with HCC secondary to other etiologies (non-viral group).
ORIGINAL:0017472
ISSN: 0360-3016
CID: 5755102
Fast Facts for Patients and Supporters: Cholangiocarcinoma: A cancer of the bile duct and liver. Information + Taking Control = Best Outcome
Denlinger, Crystal, Spencer, Kristen
ISBN:
CID: 5751472
Immuno-oncologic care during COVID-19: Challenges and opportunities for improving clinical care and investigation
Spencer, Kristen; Singer, Eric A; Girda, Eugenia
Cancer care has been greatly impacted during the COVID-19 pandemic. The number of cases and deaths caused by the COVID-19 pandemic continues to escalate throughout the United States and the world. Worldwide, over 150 million people have been diagnosed with the coronavirus and more than 3 million have died. Now that we have gained additional experience with COVID-19, we are starting to learn its full impact on oncology care and its effects on the practice of medicine and clinical research.
PMCID:8870506
PMID: 35224563
ISSN: n/a
CID: 5180662
A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study [Meeting Abstract]
Yarchoan, Mark; Cope, Leslie; Anders, Robert A.; Noonan, Anne; Goff, Laura W.; Goyal, Lipika; Lacy, Jill; Li, Daneng; Patel, Anuj; He, Aiwu R.; Abou-Alfa, Ghassan; Spencer, Kristen; Kim, Edward; Xavier, Stephanie; Ruggieri, Amanda; Davis, S. Lindsey; McRee, Autumn; Kunk, Paul; Zhu, Qingfeng; Wang-Gillam, Andrea; Poklepovic, Andrew; Chen, Helen; Sharon, Elad; Lesinski, Gregory B.; Azad, Nilo
ISI:000590059302169
ISSN: 0008-5472
CID: 5180742
A phase Ib study of troriluzole (BHV-4157) in combination with nivolumab [Meeting Abstract]
Silk, Ann W.; Saraiya, Biren; Groisberg, Roman; Chan, Nancy; Spencer, Kristen Renee; Girda, Eugenia; Shih, Weichung; Manne, Veeraswamy; Palmeri, Marisa; Berman, Robert; Coric, Vlad; Vieth, Joshua; Chen, Suzie; Mehnert, Janice M.; Malhotra, Jyoti
ISI:000529994300077
ISSN: 0732-183x
CID: 5754812